March 2, 2020
Kyowa Kirin and Ultragenyx said on February 27 that the US FDA has accepted their rickets treatment Crysvita (burosumab) for priority review for an additional indication of tumor-induced osteomalacia (TIO), with a target action date set for June 18. The...read more